Alterations of Irf8/IRF8 described in the context of non-PML/RARA and PML/RARA hematological neoplasms
| Setting . | Phenotype described . | Cell type of the phenotype (and rate if specified) . | Reference . |
|---|---|---|---|
| Non-PML/RARA leukemias/neoplasms | Myeloproliferative syndrome | Irf8+/− and Irf8−/− animals | 8 |
| IRF8 strongly downregulated or absent | Human CML (79%) and AML (66%) | 10 | |
| IRF8 downregulated | Therapy-related AML with −5/del(5q) | 11 | |
| Irf8 expression impairs BCR/ABL-mediated leukemogenesis in vivo | BCR/ABL-transfected 32D cells in murine recipients (48.5% death vs 89.8% in control) | 12 | |
| IRF8 expression impairs AML in mice | Human AML cell lines (OCI-AML3 and U937) transplanted in NSG mice | 13 | |
| Loss of Irf8 cooperates for leukemogenesis | NUP98-TOP1leukemia in murine recipients (retro virally-induced) | 14 | |
| IRF8 promoter hypermethylated | Human MDS (20%), de novo AML (25%), secondary AML (28%) | 15 | |
| IRF8 downregulated | |||
| PML/RARA expression APL | IRF8 downregulated | Human t(8;21) AML and APL | 15 |
| IRF8 as a target gene of PML/RARA | Human APL and cell line (NB4) | 16 | |
| IRF8 increased upon ATRA treatment | Human APL and cell line (NB4) | 17 | |
| Irf8 downregulated | Murine CSG-PML/RARA preleukemic CMPs and GMPs (vs WT) | 18 | |
| Irf8 downregulated | Murine MRP8-PML/RARA preleukemic promyelocytes (vs WT) | 1 | |
| Murine MRP8-PML/RARA leukemia (vs preleukemic cells) | |||
| Irf8 downregulated | Murine PML/RARA APL (vs BXH2 AML) | S.C.K. and James R. Downing, unpublished observations, 15 November 2007 | |
| Irf8 downregulated | Human PML compared with other human AMLs | TCGA data; supplemental Figure 1 |
| Setting . | Phenotype described . | Cell type of the phenotype (and rate if specified) . | Reference . |
|---|---|---|---|
| Non-PML/RARA leukemias/neoplasms | Myeloproliferative syndrome | Irf8+/− and Irf8−/− animals | 8 |
| IRF8 strongly downregulated or absent | Human CML (79%) and AML (66%) | 10 | |
| IRF8 downregulated | Therapy-related AML with −5/del(5q) | 11 | |
| Irf8 expression impairs BCR/ABL-mediated leukemogenesis in vivo | BCR/ABL-transfected 32D cells in murine recipients (48.5% death vs 89.8% in control) | 12 | |
| IRF8 expression impairs AML in mice | Human AML cell lines (OCI-AML3 and U937) transplanted in NSG mice | 13 | |
| Loss of Irf8 cooperates for leukemogenesis | NUP98-TOP1leukemia in murine recipients (retro virally-induced) | 14 | |
| IRF8 promoter hypermethylated | Human MDS (20%), de novo AML (25%), secondary AML (28%) | 15 | |
| IRF8 downregulated | |||
| PML/RARA expression APL | IRF8 downregulated | Human t(8;21) AML and APL | 15 |
| IRF8 as a target gene of PML/RARA | Human APL and cell line (NB4) | 16 | |
| IRF8 increased upon ATRA treatment | Human APL and cell line (NB4) | 17 | |
| Irf8 downregulated | Murine CSG-PML/RARA preleukemic CMPs and GMPs (vs WT) | 18 | |
| Irf8 downregulated | Murine MRP8-PML/RARA preleukemic promyelocytes (vs WT) | 1 | |
| Murine MRP8-PML/RARA leukemia (vs preleukemic cells) | |||
| Irf8 downregulated | Murine PML/RARA APL (vs BXH2 AML) | S.C.K. and James R. Downing, unpublished observations, 15 November 2007 | |
| Irf8 downregulated | Human PML compared with other human AMLs | TCGA data; supplemental Figure 1 |
AML, acute myeloid leukemia; CML, chronic myeloid leukemia; MDS, myelodysplastic syndrome; TCGA, The Cancer Genome Atlas.